Imunon, Inc. Segments Disclosure
3. SEGMENT PERFORMANCE MEASURES AND EXPENSES
The Company operates in one segment for the research and development of our product candidates. The Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated financial information. Consequently, we view the entire organization as one reportable segment and the strategic purpose of all operating activities (including general and administrative expenses) is to support that one segment. As a pre-revenue research and development company, the CODM evaluates company-wide performance and allocates resources based on non-financial research and development milestones achieved, and to a lesser extent, financial measures of performance such as clinical development (research and development expenses) and general and administrative expenses incurred. Our CODM does not generally evaluate our performance using asset or historical cash flow information.
The following table provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):
| For the year ended December 31, | ||||||||||||||||
| (In thousands) | Change Increase (Decrease) | |||||||||||||||
| 2025 | 2024 | |||||||||||||||
| Operating Expenses: | ||||||||||||||||
| Clinical Research | ||||||||||||||||
| OVATION 2 and MRD Trials | $ | 402 | $ | 1,386 | $ | (984 | ) | (71.1 | )% | |||||||
| OVATION 3 Trial | 1,313 | 1,313 | % | |||||||||||||
| PlaCCine Vaccine Phase 1 Trial | 10 | 1,420 | (1,410 | ) | (99.3 | )% | ||||||||||
| Other Clinical and Regulatory | 1,910 | 2,434 | (524 | ) | (21.5 | )% | ||||||||||
| Subtotal | 3,635 | 5,240 | (1,605 | ) | (30.6 | )% | ||||||||||
| Non-Clinical R&D and CMC | ||||||||||||||||
| OVATION Program | 2,999 | 1,819 | 1,180 | 64.9 | % | |||||||||||
| PlaCCine Vaccine Program | 2,554 | (2,554 | ) | (100.0 | )% | |||||||||||
| Manufacturing (CMC) | 1,147 | 2,026 | (879 | ) | (43.4 | )% | ||||||||||
| Subtotal | 4,146 | 6,399 | (2,253 | ) | (35.2 | )% | ||||||||||
| Research and development expenses | 7,781 | 11,639 | (3,858 | ) | (33.1 | )% | ||||||||||
| General and administrative expenses | 6,870 | 7,493 | (623 | ) | (8.3 | )% | ||||||||||
| Total operating expenses | 14,651 | 19,132 | (4,493 | ) | (23.4 | )% | ||||||||||
Loss from operations | $ | (14,651 | ) | $ | (19,132 | ) | $ | 4,493 | (23.4 | )% | ||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 31, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.